Mark Petrie is Professor of Cardiology in the School of Cardiovascular and Metabolic Health at the University of Glasgow, and a cardiologist at Glasgow Royal Infirmary, UK. Professor Petrie's has a high-volume clinical practice within a large heart failure team. Mark worked as an interventional and heart failure/transplant cardiologist for many years before transitioning to an academic post. His research interests focus on diabetes and cardiovascular disease, intervention in heart failure, AF ablation in heart failure, subcutaneous furosemide in heart failure, revascularisation in heart failure, peripartum cardiomyopathy, inflammation in heart failure, microvascular disease in heart failure with preserved ejection fraction, obesity and heart failure, cardiac remodelling, iron in heart failure and cardio-oncology. He has leadership roles in many trials including SYMPHONY, Subcut HF 1 and 2, STICH, STICH 3.0, REVIVED, DAPA-HF, EMPACT-MI, HERMES, CRAAFT-HF, STEP-HFpEF, REALIZE-K, EMPRESS-MI, IRONMAN, PARADISE-MI, FINEARTS and has chaired or been a member of over 40 Clinical Events Committees for major trials Including EMPAREG-OUTCOME and DELIVER). Mark has published over 350 original publications, many in high impact factor journals such as NEJM, Lancet, JAMA, Circulation and JACC. Mark is a Board member of the Heart Failure Association of the European Society of Cardiology and chairs its HFpEF/ HFmrEF group. He is a Board member of the British Society of Heart Failure. He co-chairs the Scottish Cardiac Audit Programme and chairs the Clinical Board of the Pumping Marvellous Foundation.